Abstract: |
GM2 ganglioside is a common cell surface constituent of human melanoma and other tumors of neuroectodermal origin, and vaccination with GM2 ganglioside results in high levels of anti-GM2 antibodies in patients with melanoma. Lymphocytes from a GM2-vaccinated patient (VS) were transformed by Epstein-Barr virus and tested for production of antibodies with reactivity for GM2-positive tumor cells. A high percentage of antibody-producing B cells was detected, but antibody reactivity was generally lost during culture expansion. Two cultures, however, remained stable for antibody productivity and one was used to develop a stable hybrid line with mouse myeloma. The monoclonal antibody (designated 3-207) derived from patient VS has dual specificity for GM2 and GD2, despite the fact that only GM2 antibody could be detected in the patient's serum. Monoclonal antibody 3-207 shows high-titered reactivity with a range of melanoma, astrocytoma, neuroblastoma, and leukemia cell lines, cells with prominent cell surface expression of GM2 and GD2. The cell surface reactivity of monoclonal antibody 3-207 was not abolished by treatment of target cells with neuraminidase, as the enzyme converted GD2 to GM2, which was still detected by monoclonal antibody 3-207. |
Keywords: |
case report; animal; mice; bcg vaccine; melanoma; cell line; tumor cells, cultured; monoclonal antibody; antibodies, monoclonal; antibody specificity; ganglioside gm3; neuraminidase; ganglioside gd3; antibody production; vaccines; cell transformation, viral; herpesvirus 4, human; cell fusion; immunization; gangliosides; tissue culture; human herpesvirus 4; cancer immunology; g(m2) ganglioside; chromatography, thin layer; human; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; epstein-barr virus transformation
|